within Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CA05_Aprobarbital;

model Aprobarbital
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 2.9166666666666666e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0006,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0011666666666666668,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Aprobarbital</td></tr><tr><td>ATC code:</td><td>N05CA05</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.15</td><td>L/kg/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Aprobarbital is a barbiturate derivative with sedative, hypnotic, and anticonvulsant properties. It was previously used for the treatment of insomnia and epilepsy, but is rarely used or approved today due to the availability of safer alternatives.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult humans based on class information for barbiturates, as no direct human PK data for aprobarbital is found in available literature.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05CA05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Aprobarbital;
